LUNG CANCER
Latest News
Latest Videos
CME Content
More News
Edward B. Garon, MD, discussed these data, as well as other trials investigating immunotherapeutic agents for patients with EGFR-mutant non–small cell lung cancer.
In a presentation during the 2nd Annual Precision Medicine Through Plasma: Using Liquid Biopsies in Contemporary Oncology Care symposium, Bob T. Li, MD, MPH, explained ctDNA’s growing importance in lung cancer, given the disease’s challenging prognosis.
Liquid biopsies have evolved beyond finding genotypes and have moved into the cancer detection and monitoring spaces, according to Geoffrey R. Oxnard, MD, medical oncologist at the Dana-Farber Cancer Institute and associate professor of medicine at Harvard Medical School.
Edward B. Garon, MD, discusses data from the IMpower150 trial where patients with <em>EGFR-</em>mutant lung cancer were randomized to 1 of 3 arms: a control of carboplatin, paclitaxel, and bevacizumab (Avastin), an arm replacing bevacizumab with atezolizumab (Tecentriq), and a third using all 4 agents.
A look back at all the FDA news in oncology from the month of January 2019, including several new approvals, breakthrough therapy designations, and a partial clinical hold.
Sukhmani Padda, MD, discusses how third-generation tyrosine kinase inhibitors compare to the first- and second-generation TKIs.
Based on data from the phase III KEYNOTE-189 trial, the FDA has expanded the approval for pemetrexed injection in combination with pembrolizumab and platinum-based chemotherapy to include the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer without <em>EGFR</em> or <em>ALK</em> alterations.
During a presentation at the <em>16th Annual </em>Winter Lung Cancer Conference, Julie R. Brahmer, MD, MSc shed light on some of the immunotherapy treatment options that could be entering the lung cancer pipeline over the next 5 years.
Edward B. Garon, MD, discusses the newer role of immunotherapy in the treatment of patients with unresectable stage III NSCLC with the approval of durvalumab in this setting for patients whose disease has not progressed following concurrent chemoradiation.
Christina S. Baik, MD, MPH, discusses several existing and emerging treatment options for <em>ROS1</em>, <em>BRAF</em>, and <em>NTRK </em>genetic aberrations.
Bristol-Myers Squibb has announced its decision to withdraw a supplemental biologics license application currently with the FDA seeking frontline approval for the combination of nivolumab and ipilimumab for patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.
Michael Gieske, MD, discusses how his community center was able to implement a lung cancer screening program.
A retrospective analysis of survival data from patients with metastatic non–small cell lung cancer showed that patients who received treatment at academic centers had better survival rates than those treated at community-based centers, and this disparity was more pronounced when patients were stratified by histology.
A supplemental biologics license application submitted to the FDA for atezolizumab, carboplatin, and nab-paclitaxel has been accepted. The application, based on findings from the phase III IMpower130 trial, is seeking the agent's approval for patients with metastatic nonsquamous non–small cell lung cancer.
Increasing clinical relevance of less common gene signatures and alterations is leading to a benefit from broad-panel next-generation sequencing testing for patients with metastatic non–small cell lung cancer, according to an expert at Memorial Sloan Kettering Cancer Center.
The use of big data is revolutionizing many industries, allowing greater insights by drilling into evidence with more detail.
Due to the significant decline in smoking and an increase in advances for early cancer detection and screening, the cancer death rate has declined 27% in the United States from 1991 to 2016, according to the American Cancer Society’s annual report on cancer rates.